Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Colorcon
Argus Health
Boehringer Ingelheim
Citi
Mallinckrodt
Merck
Queensland Health
Harvard Business School

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021286

« Back to Dashboard

NDA 021286 describes BENICAR, which is a drug marketed by Daiichi Sankyo and is included in two NDAs. It is available from eight suppliers. Additional details are available on the BENICAR profile page.

The generic ingredient in BENICAR is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.
Summary for 021286
Tradename:BENICAR
Applicant:Daiichi Sankyo
Ingredient:olmesartan medoxomil
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021286
Medical Subject Heading (MeSH) Categories for 021286
Suppliers and Packaging for NDA: 021286
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BENICAR olmesartan medoxomil TABLET;ORAL 021286 NDA Med-Health Pharma, LLC 51138-211 E 51138-211-30
BENICAR olmesartan medoxomil TABLET;ORAL 021286 NDA Med-Health Pharma, LLC 51138-212 E 51138-212-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Apr 25, 2002TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Apr 25, 2002TE:ABRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Apr 25, 2002TE:ABRLD:Yes

Expired US Patents for NDA 021286

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-004 Apr 25, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-001 Apr 25, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo BENICAR olmesartan medoxomil TABLET;ORAL 021286-003 Apr 25, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Deloitte
McKinsey
Mallinckrodt
Cantor Fitzgerald
US Department of Justice
AstraZeneca
US Army
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.